Medical device company Globus Medical (NYSE:GMED) reported Q4 CY2024 results , with sales up 6.6% year on year to $657.3 ...

Globus Medical saw fourth quarter net sales grow 6.6% year over year, and full year sales leapt 60.6%, according to financial results posted Feb. 20.

Reports Q4 revenue $657.29M, consensus $646.19M. “I’m proud of our team at Globus Medical (GMED), delivering incredible results for 2024. We ...

Globus Medical expects full-year earnings in the range of $3.40 to $3.50 per share, with revenue in the range of $2.66 billion to $2.69 billion. This story was generated by Automated Insights ( http:/ ...

Globus Medical Inc. (NYSE:GMED), a leading medical device company specializing in musculoskeletal disorders, has been making waves in the healthcare sector with its recent acquisition of Nevro Corp ...

Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...

AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp. (NYSE: NVRO), a global medical device ...

(RTTNews) - Globus Medical (GMED), a musculoskeletal solutions company, Thursday agreed to acquire Nevro Corp. (NVRO), a medical device company, in an all-cash transaction. Under the terms of the ...

AUDUBON, Pa. and REDWOOD CITY, Calif., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Globus Medical (NYSE: GMED), a leading musculoskeletal solutions company, and Nevro Corp ...

Globus Medical will acquire Nevro for $250 million in cash, enhancing its musculoskeletal technology portfolio andglobal marketreach. Globus Medical and Nevro Corp. have agreed on an all-cash ...

Globus Medical said the purchase would increase its portfolio of musculoskeletal technologies, therefore enhancing its position in neuromodulation and chronic pain management. Nevro, with its HFXTM ...

Globus Medical (GMED) and Nevro Corp. (NVRO) have entered into a definitive agreement for Globus Medical to acquire all shares of Nevro in an all-cash transaction. Under the terms of the agreement ...